What is Sinovac Biotech?
Sinovac Biotech Ltd. operates as a China-based biopharmaceutical leader dedicated to the research, manufacturing, and commercialization of vaccines targeting human infectious diseases. With a comprehensive product suite that includes CoronaVac and various influenza vaccines, the company has established a strong market presence both domestically and across emerging markets in Asia, Latin America, and Africa. Its commitment to quality is evidenced by WHO prequalification for its hepatitis A vaccine and its pioneering role in developing vaccines for H1N1 and H5N1 pandemic influenza. The firm's operational strategy centers on maintaining a high-volume manufacturing capacity while simultaneously advancing a pipeline of combination vaccines to meet evolving public health needs.
How much funding has Sinovac Biotech raised?
Sinovac Biotech has raised a total of $515M across 2 funding rounds:
Debt
$15M
Private Equity
$500M
Debt (2020): $15M with participation from Vivo Capital LLC and Advantech Capital
Private Equity (2020): $500M led by Sino Biopharmaceutical Limited
Key Investors in Sinovac Biotech
Sino Biopharmaceutical Limited
A leading pharmaceutical company focused on the research, development, and production of a wide range of medicines and healthcare products.
Advantech Capital
Advantech Capital is a private equity fund, focused on innovation-driven growth capital in China, managing investments across TMT, E-services, and Healthcare sectors.
Vivo Capital LLC
A global investment firm specializing in the healthcare industry, providing capital to companies across all stages of development.
What's next for Sinovac Biotech?
Looking ahead, Sinovac Biotech is poised to leverage its recent capital injection to accelerate the registration and market authorization of its product portfolio in new international territories. The strategic focus remains on scaling production efficiencies and investing in R&D for next-generation combination vaccines. As the company navigates the complexities of global regulatory environments, this financial support provides the necessary liquidity to sustain its competitive advantage in the biopharmaceutical sector. Future growth will likely be driven by the successful integration of new vaccine candidates into its existing commercial framework, further solidifying its role as a key supplier in global government vaccination programs.
See full Sinovac Biotech company page
